Notably, no extra‐tumour toxicity or xenograft‐versus‐host response was demonstrated in experiments using the universal CAR dual‐targeting CD33 and CD123 to lysate AML primary cells and AML cell lines. Here, CD33 is linked to acute myeloid leukemia.